CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues Oct 28, 2022 5:15pm EDT
CytoDyn Announces Appointment of Additional Directors with Industry Experience Oct 20, 2022 8:30am EDT
CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab Jul 11, 2022 8:30am EDT
CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer May 23, 2022 8:30am EDT
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor May 13, 2022 8:00am EDT
CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species” Apr 12, 2022 8:30am EDT
